Aptevo Therapeutics (APVO) Change in Cash (2015 - 2026)

Aptevo Therapeutics has reported Change in Cash for 12 years, with the latest figure at -$7.1 million in Q1 2026.

• Quarterly Change in Cash fell 7.89% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (up 252.71% YoY) and the FY2025 annual result came in at $12.9 million, up 257.57% from the prior year.
• Change in Cash slipped to -$7.1 million in Q1 2026 per APVO's latest filing, from $558000.0 in the prior quarter.
• Over five years, Change in Cash peaked at $11.7 million in Q3 2025 and troughed at -$10.1 million in Q1 2022.
• A 5-year average of -$1.9 million and a median of -$2.2 million in 2024 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2023 and 2025: Change in Cash plunged 3840.68% in 2023, then jumped 3822.36% in 2025.
• Over 5 years, Change in Cash stood at $59000.0 in 2022, then slumped by 3840.68% to -$2.2 million in 2023, then surged by 143.54% to $961000.0 in 2024, then sank by 41.94% to $558000.0 in 2025, then sank by 1371.33% to -$7.1 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$7.1 million, $558000.0, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.